Tiludronate. A new treatment for an old ailment: Paget's disease of bone

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 1, 1999, Pages 157-170

  Morales Piga, A ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Osteoclast inhibitors; Paget's disease; Tiludronate; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; TILUDRONIC ACID;

ANIMAL; CLINICAL TRIAL; HUMAN; METABOLISM; OSTEOLYSIS; PAGET BONE DISEASE; PATHOLOGY; REVIEW;

ANIMALS; BONE RESORPTION; CLINICAL TRIALS; DIPHOSPHONATES; HUMANS; OSTEITIS DEFORMANS;

EID: 0033224468     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.1.157     Document Type: Article

References (71)

1. FLEISCH H: Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin. Orthop. (1987) 217:72-78. An expert and comprehensive review of the rationale for using bisphosphonates in Paget's disease.
2. SINGER FK, KKANE SM: Paget's disease of bone. In: Metabolic Bone Diseuse. Avioli LV, Krane SM (Eds.), Academic Press, San Diego, USA (1998):545-605.
3. KANIS JA: Pathophysiology and treatment of Paget's disease of bone. Martin Dunitz, London, UK (1998).
4. FLEISCH H, RUSSELL RGG, FRANCIS MD: Diphosphonatcs inhibit hydroxyapatitc dissolution in vitro and bone résorption in tissue culture and in vivo. Science (1969) 165:1262-1261.
5. HUGHES DE, MAC DONALD BR, RUSSELL RGG, GOWEN M: Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. din. Incest. (1989) 83:1930-1935. • Tliis paper provides evidence that bisphosphonates are potent inhibitors of proliferation and differentiation of osteoclast-like cells.
6. FLANAGAN AM, CHAMBERS TJ: Dichloromcthylencbisphosphonatc (CljMBP) inhibits bone résorption through injury to osteoclast that resorb CljMBP-coated bone. Bone.Min. (1989) 6:33-43.
7. HUGHES DE, WRIGHT KR, UY HL étal.: Bisphosphonates promote apoptosis in murinc osteoclast in vitro andJJ vii'o.J. Bone Miner. Res. (1995) 10:1478-1487.
8. VITTe C, FLEISCH H, GUENTHER H. Bisphosphonates induce ostcoblasts to secrete an inhibitor of osteoclast-mcdiated résorption. Endocrinology (1996) 137:2324-2333.
9. MEUNIER PJ, VIGNOT E: Therapeutic strategy in Paget's disease of bone. #o;ie(1995) 17(Suppl.):489-491.
10. FLEISCH H. Bisphosphonates. Pharmacology and use in treatment of tumour-induced hypercalcémie and mctastatic bone disease. Dntgs (1991) 42:919-944.
11. REGINSTER JY: Oral tiludronatc: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone (1992) 13:351-354. • Tills review contains interesting information on pharmacological and pharmacokinetic properties of tiludronate.
12. BONJOUR JI', AMMANN P, HAKBIER A, CAVERZASIO J, RIZZOLI R: Tiludronate: bone pharmacology and safety. Bone (1995) 17(Suppl.):473-477. • A review of the literature on preclinical studies with tiludronate.
13. EMONTS-ALT X. BRELIÈRE JC, RONCUCCI R: Effects of 1-hydroxyethylidcne-l, Ibisphosphonate and (chloro-4 plienyl) thiomethylene bisphosphonic acid (SR41319B) on the mononucleâr cell factor mediated release of neutral protcinases by articular chondrocytcs and synovial cells. Biocbem. Pbarmacol. (1985) 34:4043-4049.
14. BARBIER A, EMONTS-ALT X, BRELIeRE JC, ETHGEN D: In vitro and in vivo osseous pharmacological profile of tiludronate. Implication for osteoporosis treatment. In: Osteoporosis. Christiansen C, Overgaard K (Eds.), Osteopress ApS Publications (1990) 2:1127-1129. • This study describes an elegant set of experiments showing the different mechanisms of action of tiludronate on bone resorption.
15. MURAKAMI H, UDAGAWA N, TAKAHASHI N, TANAKA S, SUDA T: Tiludronate inhibits bone résorption without suppressing osteoclast formation in vitro. 4th InteniationalSymposium on Osteoporosis. Hong Kong (1993): 141.
16. MURAKAMI H, TAKAHASHI N, SASAKI T et eil.: A possible mechanism of the specific action of bisphosphonatcs on ostcoclasts: tiludronate preferentially affects polarized ostcoclasts having ruffled borders. Bone (1995) 17:137-144. This is an important paper that provides suggestive evidence that tiludronate is a specific inhibitor of functioning osteoclasts.
17. +-ATPase. J. Hone Miner. Res. (1996) 11:1498-1507. This study, designed to investigate the molecular modes of action of tiludronate, showed that the compound directly inhibit osteoclast vacuoIar-ATPase-mediated proton transport.
18. GODET D, HOTT M, GRAULET A, GUERIS J, MARIE P: Effects of bisphosphonatcs on cell proliferation, differentiation and cytokines production in rat and human calvaria ostcoblastic cells (abstract). Second Workshop on Bisphosphonates. Davos, Switzerland (1994).
19. TRECHSEL U, STUTZER A, FLEISCH H: Hypercalcemla induced with an arotinoid in thyroparathyroidectomizcd rats: a new model to study résorption in vivo. J. Clin. Invest. (1987) 80:1676-1686.
20. AMMANN P, RIZZOLI R, CAVERZASIO J, SHIGEMATSU T, SLOSMAN D, BONJOUR JP: Effects of the bisphosphonatc tiludronate on bone résorption, calcium balance and bone mineral density. J. Bone Miner. Res. (1993)8:1491-1498.
21. BOONEKAMP PM, VAN DER WEE-PALS LJA, VAN WIJK-VAN LENNEP MML, THESING CW, BIJVOET OLM: Two models of action of bisphosphonatcs on ostcoclastic resorption of mineralized matrix. Bone Miner. (1986) 1:27-39.
22. RODAN GA, SEEDOKJG, BALENA R: Prcclinical pharmacology of alendronatc. Ostt'Oporosis Int. (1993) 3(Suppl.3):7-12.
23. SIETSEMA WK, EBETINO FH, SALVAGNO AM, BEVAN JA: Antircsorptive dose-response relationships across three generations of bisphosphonatcs. Drugs Exf>. Clin. Res. (1989) 15:389-396.
24. BARBIER A, BONJOUR JP, GEUSENS P, DE VERNEJOUL MC, LACHERETZ F: Tiludronate: Abisphosphonatc with a positive effect on bone quality in experimental models.J Rone Miner. Kcs. (1991) 6(Suppl.l):217.
25. EMONTS-ALT X, BARBIER A, BRELIERE JC, RONCUCCI R: Anti-arthritic and anti-ostcoporotic activities of (chloro-4 phenyl) thiomethylene bisphosphoiiic acid (SR41319B). Pharmacological studies. Calcif. Tissue Int. (1985) 38(Suppl.):34.
26. OHNISHI H, NAKAMURAT.TSURUKAMI H.MURAKAMI H, ABE M, BARBIER A: Effect of a bisphosphonatc tiludronatc on bone mass and strength in established osteoporosis of ovariectomized rats.J Bone Miner. Res. (1994) 9(Suppl.l):267.
27. MURAKAMI H, NAKAMURA T, TSURUKAMI H, ABE M, BARBIER A, SUZUKI K: Effects of tiludronatc on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic ncurectomy. J Bone Miner. Res. (199 9:1355-1364.
28. DELMAS P, VERGNAUD P, ARLOT M, PASTOUREAU P, MEUNIER P: The in vivo anabolic effect of hPTH(1.34) is blunted when bone résorption is blocked by a bisphosphonatc. J. Bone Miner. Res. (1991) 6(Suppl.l):136.
29. DE VERNEJOUL MC, JIANG Y, LACHERETZ F et al.: Prevention of bone loss following tiludronate administration to ovariectomized beagle dogs. In: Osteoporosis. Christiansen C, Overgaard K (Eds.), Osteopress ApS Publications (1990) 2:1119-1122.
30. CHARHON S, MEUNIER P, ETHGEN D, LACHERETZ F, BREL1eRE JC, RONCUCCI R: Histomorphometric analysis of bone biopsies of baboons treated with SR 41319B, anewbisphosphonate. Calcif. Tissitelnt. (1985) 38(SuppI.):33.
31. GEUSENS P, NIJSJ, VAN DER PERRE G el al.: Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys. J Bone Miner. Res. (1992) 7:599-609.
32. NEER KM: Skeletal safety of tiludronatc. Bone (1995) 17:501S-503S. This review summarises the preclinical and clinical research on the skeletal safety profile of tiludronate.
33. MORALES PICA A. DEL PINO J, RAPADO A, DIAZ-CURIEL M, PALLARES M, GONZALEZ-MACiAS J: Comparison of the efficacy and bioequivalencc of two oral formulations of Tiludronatc in the treatment of Pagct's disease of bone. Clin. Tberap. (1997) 19:963-974.
34. FELS JP, GUYONNET J, BERGER Y, CAUTREELS W: Determination of SR41319, a new bisphosphonate in biological fluids by HPLC.J Chromai. (1988) 430:73-79.
35. SANSOM LN, NECCIARI J, THIERCELIN JF: Human pharmacokinetics of tiludronatc. Bo;;e(1995) 17(Suppl. 5):479S-483S. • This article reviews the background to pharmacokinetic properties of tiludronnte.
36. THIERCELIN JF, ZUIDERWIJK PB, PEETERS PA el ah. Tolerance and pharmacokinetics of tiludronate after multiple doses administration of 200,400,600 and 800 mgJday to healthy volunteers' 5th World Conference on Clinical Pharmacology and Tberapeiilics. Yokohamajapan (1992).
37. BOULENC X, MARTI E, JOYEUX H, ROQUES C, BERGER Y, FABRE G:: Importance of the paracellular pathway for thé transport of a new bisphosphonatc using the human Caco-2 monolaycrs model, l'baniiacol. liiocbcm. (1992) 46:1591-1600.
38. FLEISCH H: Pharmacokinetic. In: Btspbospbonates in Bone Disease'. Fmin the Laboratory from the Patient. (2nd Edition). Fleisch H (Ed.), The Parthenon Publishing Group, London, UK (1995).
39. NECCIARI J, MOUGEOT V, PINQUIER JL, LACROIX E, ARNOUX P, DELAUTURE D: Influence of food intake (hypocalcémie or normal meal) on the bioavailability of Tiludronatc. 5tb World Conference on Clinical Pharmacology and nerafieiitlcs. Yokohama, Japan (1992).
40. HYLDSTRUP L, FLESCH G, HÄUFTE: Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability and effect of repeated administration. Calcif. Tissue Int. (1993) 53:297-300.
41. GERTZ BJ, HOLLAND SD, KLINE WF, MATUSZEWSKI BK, PORRAS AG: Clinical pharmacology of alendronate sodium. Osteopomsis Int. (1993) 3(Suppl.3):13-l6.
42. NECCIARI J, LASCOMBES F, MONTELS R, SERRES E, ARNOUX P, DELAGOUTTE JP: Bone concentrations of tiludronic acid after single and repeated administration in humans. Proceedings of the 12th International Conference on Calcium Regulating Hormones, Melbourne. Bone (1995) l6(Suppl.):197.
43. AURIOLA S, FRITH J, ROGERS MJ, KOIVUNIEMI A, MÖNKKÖNEN J: Identification of adenine nucleotidecontaining metabolites of bisphosphonatc drugs using ion-pair liquid chromatography-clccrospray mass spectrometry. J Chrom. 0(1997) 704:187-195.
44. PAPALEXIOU P, DEI3RY G, NECCIARI J, SERRES E, GOLDSTEIN N, MAIER G: Tiludronate: pharmacokinetics in patients with Pagct's disease of bone. Comparison with healthy volunteers. J Bone Miner. Kes. (1996) IKSuppl. 1):373.
45. CHASSARD D, LASCOMBES F, CREEK R, NECCIARI J, SERRES E: Study of the pharmacokinetic interactions between tiludronate and the non-steroidal anti-inflammatory drugs: aspirin, diclofcnac and ïndomcthacïn.J.BoneMiner. Kes.(1996) IKSuppl. 1):347.
46. REGINSTERJY.JEUGMANS-HUYNEN AM, ALBERT A et al.: Biological and clinical assessment of a new bisphosphonatc, (chloro-4 phenyl) thiomcthylene bisphosphonatc, In the treatment of Paget's disease of bone. Bow (1988) 9:349-35-4. • First report showing that tiludronate is active in Paget's disease.
47. AUDKAN M, CLOCHON P, ETHGEN D, MAZIERES B, KENIER JC: Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylcne bisphosphonatc. Clin. Kbcumalol. (1989) 8:71-79.
48. REGINSTER JY, COLSON F, MORLOCK G, COMBE B, ETHGEN D, GEUSENS P: Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. Arthritis Kheuin. (1992) 35:967-974. Results of a double-blind, placebo-controlled study showing clinical and biochemical efficacy of tiludronate in a large group of Paget's disease patients.
49. REGINSTER JY, TREVES R, RENIER JC et ah Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. J. Bone Miner. Kcs. (1994) 9:615-619.
50. MC CLUNG M, TOU C, GOLDSTEIN N, PICOT C: Tiludronate therapy for Paget's disease of bone. Bone (1995) 17(Suppl.):493-496. • The results of a double-blind placebo-controlled study showing the safety and efficacy of 400 mgJday of tiludronate administered for 3 months in Paget's disease patients.
51. FRASER WD, STAMP TC, CREEK RE, SAWYER JP, PICOT C: A double-blind, multiccntrc, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad. A led. J. (1997) 73:496-502. • A carefully conducted double-blind placebo-controlled study demonstrating that 400 inJday of tiludronate for 3 months offers the optimum balance between efficacy and tolerance.
52. ROUX C, GENNARI C, FARRERONS J et al.: Comparative, prospective, double-blind, multiccnter study of the cfficay of tiludronate and ctidronatc in the treatment of Paget's disease of bone. Arthritis Rheum. (1995) 38:851-858. A very well-designed and carefully conducted comparative study demonstrating that, in Paget's disease, tiludronate is more effective and equally safe than etidronate at equivalent doses.
53. ROUX C: The methodology of clinical trials of oral tiludronate in Paget's disease of bone. Bone (1995) 17(Suppl.5):497-499.
54. REGINSTER JY, LECART MP, DEROISY R, ETHGEN D, EGELS B, FRANCHIMONT P: Paget's disease of bone treated with a five day course of oral tiludronate. Ann. Rheum. Dis. (1993) 52:54-57.
55. STAMP TC, FRASER WD, SAWYER JP, CREEK RA, PICOT C: Tiludronate Tablet (Skelid) 400 mgJday produces lengthy clinical remission of Paget's disease: follow-up to a dose-ranging study. J. Bone Miner. Kcs. (1996) ll(Suppl.l):372.
56. MORALES PICA A, ABRA1RA SANTOS V, REY KEY J, DE AI5AJO IGLESIAS F: Factures que dctcrminan la intcnsidad de la respuesta al tratamicnto con tiludronato en la Enfermedad de Paget. Meil. Clin. (1998) 110:254-258.
57. CHAPPARD D, MINAIRE P, PRIVAT C et ai: Effects of tiludronatc on bone loss in paraplegic patients.y. Bone Miner. Res. (1995) 10:112-118.
58. PETERFY CG, GENANT HK, STEINER E, KREUGER KA, LU Y: Blinded radiographie evaluation of the efficacy of tiludronatc disotlium for the ' treatment of Paget's disease of bone. Proceedings of the 12th International Conference on Calcium Regulating Hormones, Melbourne. Bow (1995) l6(Suppl.):154.
59. DEVOGELAER JP, MALGHEMJ, STASSE P, NAGANT-DEDEUXCHAISNES C: Biological and radiological responses to oral ctidronate and tiludronatc in Paget's disease of bone, flow (1997; 20:259-261.
60. AUDRAN M, COMBE I, MICHAUT S, DRICOT J, DEVOGELAER JP, REGINSTER JY: Low risk of fractures in long-term treatment of Paget's disease of bone with tiludronatc.J Bone Miner. Res. (1996) IKSuppl. 1):372.
61. JOHNSTON CC, ALTAIAN RD, CANFIELD RE, FINEKMAN GAM, TAULI5EE JD, EBERT ML: Review of fracture experience during treatment of Paget's disease of bone with ctidronate disodium (EHDP). Clin. Ortbop. (1983) 172:186-194.
62. ROUX C, LISTRAT V, VILLETTE B et al.: Long-lasting dcrmatological lesions after tiludronatc therapy.
63. Calcif. Tissue Intern. (1992) 50:378-380.
64. PLOSKER GI, GOA KL. Clodronate. Review of its pharmacological properties and therapeutic efficacy in resorptive bone discase.DrHgs (199-0 47:945-982.
65. DELMAS PD, CHAPUY MC, VIGNON E et eil.: Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone.J Clin. Enilocrinol. Metab. (1982) 54:837-843.
66. HARINCK HI, BIJVOET OL, BLANKSMA HJ, DAHLINGHAUS-NIENHUYS PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin. Ortbop. (1987; 217:79-97.
67. LUFKIN EG, ARGUETA R, WHITAKER MD et al.: Pamidronatc: an unrecognized problem in gastrointestinal tolcrability. Osteoporosis Int. (1994) 4:320-322.
68. ADAMSON BB, GALLACHER SJ, BYARS J, RALSTON SH, BOYLE IT, BOYCE BF: Mineralisation defects with pamidronatc therapy for Paget's disease. iflJ(ceJ(1993) 342:1459-1460.
69. REID IR, NICHOLSON GC, WEINSTEIN RS, HOSKING DJ, CUNDY T, KOTOWICZ MA et al.: Biochemical and radiologie improvement in Paget's disease of bone treated with alcndronatc: a randomized placebocontrolled trial Am.J. Mecl. (1996) 171:341-348.
70. HOSKING DJ, EUSEBIO RA, CHINES AA: Paget's disease of bone: Reduction of disease activity with oral risedronatc. Bone (.1998) 22:51-55.
71. BICKERSTAFF DR. DOUGLAS DL, BURKE PH, OTJOHERTY DP, KANIS JA: Improvement in the deformity of the face in Pagct's disease treated with diphosphonates.y. Bone Joint Sing. (1990) 72-B:132-136.